{"id":2624,"date":"2015-06-04T18:56:00","date_gmt":"2015-06-04T18:56:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2624"},"modified":"2025-01-16T15:34:50","modified_gmt":"2025-01-16T15:34:50","slug":"disease-burden-of-chronic-hepatitis-c-in-brazil","status":"publish","type":"post","link":"https:\/\/cdafound.org\/es\/disease-burden-of-chronic-hepatitis-c-in-brazil\/","title":{"rendered":"Carga de enfermedad de la hepatitis C cr\u00f3nica en Brasil"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Resumen<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Fondo<\/h3>\n\n\n\n<p>La infecci\u00f3n por el virus de la hepatitis C es una de las principales causas de cirrosis; carcinoma hepatocelular; y trasplante de h\u00edgado. El objetivo de este estudio fue estimar la progresi\u00f3n de la enfermedad por el virus de la hepatitis C y la carga de la enfermedad desde una perspectiva nacional.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">M\u00e9todos<\/h3>\n\n\n\n<p>Utilizando un modelo desarrollado para pronosticar la progresi\u00f3n de la enfermedad por el virus de la hepatitis C y el n\u00famero de casos en cada etapa de la enfermedad hep\u00e1tica; Se cuantific\u00f3 la poblaci\u00f3n infectada por el virus de la hepatitis C y la progresi\u00f3n de la enfermedad asociada en Brasil. Se compar\u00f3 el impacto de dos estrategias diferentes: mayor respuesta virol\u00f3gica sostenida y tasas de elegibilidad para el tratamiento (1) o tasas m\u00e1s altas de diagn\u00f3stico y tratamiento asociadas con mayores tasas de respuesta virol\u00f3gica sostenida (2).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Resultados<\/h3>\n\n\n\n<p>Se estima que el n\u00famero de personas infectadas disminuir\u00e1 en 35% para 2030 (1.255.000 personas); mientras que el n\u00famero de casos de cirrosis compensada (n = 325,900) y descompensada (n = 45,000); carcinoma hepatocelular (n = 19.100); y se supone que las muertes relacionadas con el h\u00edgado (n = 16.700) alcanzar\u00e1n su punto m\u00e1ximo entre 2028 y 2032. En la estrategia 2; los casos tratados aumentaron m\u00e1s de diez veces en 2020 (118,800 tratados) en comparaci\u00f3n con 2013 (11,740 tratados); con una respuesta virol\u00f3gica sostenida aumentada a 90% y la elegibilidad de tratamiento a 95%. Bajo esta estrategia; el n\u00famero de personas infectadas disminuy\u00f3 en 90% entre 2013 y 2030. En comparaci\u00f3n con el caso base; las muertes relacionadas con el h\u00edgado disminuyeron en 70% para 2030; mientras que el c\u00e1ncer de h\u00edgado relacionado con el virus de la hepatitis C y la cirrosis descompensada disminuyeron en 75 y 80%; respectivamente.<\/p>\n\n\n\n<p><strong>Pa\u00edses:<\/strong> Brasil<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26051505\" target=\"_blank\" rel=\"noreferrer noopener\">Lea el informe completo<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Background Hepatitis C virus infection is a major cause of cirrhosis; hepatocellular carcinoma; and liver transplantation. The aim of this study was to estimate hepatitis C virus disease progression and the burden of disease from a nationwide perspective. Methods Using a model developed to forecast hepatitis C virus disease progression and the number of [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3105,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10],"publication-author":[2098,2100,2099,535,755,2097,2096,765,763,494,2101],"class_list":["post-2624","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","publication-author-brandao-mello-ce","publication-author-cheinquer-h","publication-author-coelho-hs","publication-author-estes-c","publication-author-ferraz-ml","publication-author-ferreira-pr","publication-author-goncales-junior-fl","publication-author-mendes-correa-mc","publication-author-pessoa-mg","publication-author-razavi-h","publication-author-wolff-fh"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/comments?post=2624"}],"version-history":[{"count":6,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2624\/revisions"}],"predecessor-version":[{"id":7609,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2624\/revisions\/7609"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media\/3105"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media?parent=2624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/categories?post=2624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/tags?post=2624"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/publication-author?post=2624"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}